Showing results (1211-1220 of 3,351) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|October 17, 2002
The economic costs of early stage prostate cancerChristopher S Saigal, Mark S LitwinPharmacoeconomics|October 17, 2002
The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictionsEdward C F Wilson, Emma S McKeen, Paul A Scuffham, et al.Pharmacoeconomics|October 17, 2002
Galantamine: a pharmacoeconomic review of its use in Alzheimer's diseaseKatherine A Lyseng-Williamson, Greg L PloskerPharmacoeconomics|January 8, 2003
European healthcare policies for controlling drug expenditureSilvia M Ess, Sebastian Schneeweiss, Thomas D SzucsPharmacoeconomics|March 31, 2001
Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspectiveC Chevat, B M Peña, M J Al, et al.Pharmacoeconomics|March 31, 2001
Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in SwitzerlandJ V Chancellor, E Hunsche, E de Cruz, et al.Pharmacoeconomics|April 17, 2001
Economic burden of chronic obstructive pulmonary disease. Impact of new treatment optionsM Friedman, D E HillemanPharmacoeconomics|April 17, 2001
Cost-benefit analysis of active vaccination campaigns against hepatitis A among daycare centre personnel in IsraelG Chodick, Y Lerman, T Peled, et al.Pharmacoeconomics|March 3, 2001
Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implicationsL A Sanchez, M Holdsworth, S B BartelPharmacoeconomics|March 3, 2001
Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthmaA Markham, J C AdkinsPageof 336